Anti-cancer drug delivery agents

In the past, our limited understanding of the processes involved in the initiation and growth of cancer hindered our ability to effectively treat most human malignancies and therapies were often associated with significant toxic side effects as well as re-emergence of disease. For years, chemotherapy has been a mainstay treatment option for inoperable cancers. The development of drug delivery systems such as liposomes has improved the specificity of various conventional anticancer agents by enhancing drug accumulation in tumours while often decreasing exposure to susceptible healthy tissues. More recently, the identification of a wide range of genes and corresponding protein products that are altered in various human cancers has revealed new molecular targets for cancer therapy that may provide improved selectivity for tumour cells over traditional cytotoxic agents. 

  • Track 1-1 Nano-packages for anti-cancer drug delivery
  • Track 2-2 Liposomal DDS & anticancer drugs
  • Track 3-3 Applications of nanoparticles for anticancer drug delivery
  • Track 4-4 Targeted DDS for platinum-based anticancer drugs
  • Track 5-5 Challenges and strategies in anti-cancer nanomedicine development

Related Conference of Pharmaceutical Sciences